CAR-T Therapy FAQ

CAR T-cell therapy is an advanced immunotherapy in which a patient’s own T cells are genetically modified to better recognize and attack cancer cells, then reinfused back into the body.

It is primarily used for certain blood cancers, including specific types of leukemia and lymphoma. It is FDA-approved and shows high response rates in eligible patients.

Success varies by cancer type, but in some forms of leukemia, response rates can reach up to 90% in eligible patients.

Common side effects may include cytokine release syndrome (fever, fatigue), neurological symptoms, and temporary immune suppression. These are closely monitored by the medical team.

The full process — cell collection, laboratory modification, preparatory treatment, and infusion — typically takes several weeks.

CAR-T cell manufacturing involves leukapheresis, genetic modification, cell expansion, and reinfusion into the patient.

CAR-T therapy process takes several weeks, from cell collection to infusion, requiring coordination and patient preparation.

CAR-T cells are genetically engineered from blood T cells to target specific antigens, whereas TILs are T cells taken directly from the tumor and expanded before being given back to the patient.

Yes. CAR-T therapy is a new immunotherapy approved by the FDA for relapsed leukemia with remission rates up to 90%.

Patients with relapsed or refractory B-cell ALL, including children, young adults, and adults depending on clinical criteria.

Yes, but it may cause CRS and neurotoxicity, which are manageable with proper monitoring.

Some patients remain cancer-free for 4–6 years based on long-term follow-up of clinical trials.

Management depends on the treatment and may include anti-nausea drugs, growth factors, blood products, steroids, and close monitoring by a multidisciplinary team.

Yes. Immune-related side effects affecting the skin, thyroid, colon, liver, lungs, and other organs can occur later and may require long-term monitoring

It involves scheduled clinical exams, imaging tests, and sometimes tumor markers, according to cancer-specific guidelines.

Medical oncologists, surgeons, radiation oncologists, nurses, palliative care specialists, dietitians, physical therapists, social workers, and clinical research staff.

CAR-T treatment prices vary by center, product, and hospitalization needs. Most FDA-approved CAR-T therapies globally fall within $100,000–$190,000, excluding travel and supportive care.

CAR-T involves cell engineering, personalized manufacturing, and specialized hospital care—making the average price six figures worldwide.

The U.S. remains the most expensive market (up to $450K total package), while European centers offer $100–190K ranges. Türkiye remains competitive with lower facility costs.

When compared to survival rates and long-term remission data, many patients find CAR-T cost justified—especially after relapse post-chemotherapy or transplant.

The final cost depends on cell processing, lymphodepletion chemo, ICU availability, CRS/ICANS management, and length of stay. Typical range: $100–190K.

Many countries partially reimburse CAR-T due to strong clinical outcomes. Some insurers cover up to 70–90% depending on diagnosis.

Emerging centers in Eastern Europe and Türkiye offer high-quality CAR-T programs within the $100K–$190K standard global range, easing financial burden.

Patients often ask what this price covers:
 – Pre-testing
 – Cell collection
 – Manufacturing
 – Chemotherapy
 – Infusion
 – Hospital monitoring
 – CRS treatment

For refractory leukemia/lymphoma, CAR-T remains the most effective therapy—alternatives rarely match remission rates.

Because they are personalized, require complex manufacturing, high-tech one-time procedures, and specialized facilities, which significantly increase costs.

The FDA has approved multiple CAR-T therapies for leukemia, lymphoma, and myeloma, marking a major breakthrough in cancer treatment.

Hundreds of clinical trials worldwide are exploring CAR-T therapy for both blood cancers and solid tumors, expanding the treatment potential.

CAR-T cell manufacturing involves leukapheresis, genetic modification, cell expansion, and reinfusion into the patient.

Medical oncologists, surgeons, radiation oncologists, nurses, palliative care specialists, dietitians, physical therapists, social workers, and clinical research staff.